Physiotherapy breathing retraining for asthma: a randomised controlled trial

Anne Bruton, Amanda Lee, Lucy Yardley, James Raftery, Emily Arden-Close, Sarah Kirby, Shihua Zhu, Manimekalai Thiruvothiyur, Frances Webley, Lyn Taylor, Denise Gibson, Guiqing Yao, Mark Stafford-Watson, Jenny Versnel, Michael Moore, Steve George, Paul Little, Ratko Djukanovic, David Price, Ian D Pavord, Stephen T Holgate, Mike Thomas

Summary

Background Despite effective pharmacotherapy, asthma continues to impair quality of life for most patients. Non-pharmacological approaches, including breathing retraining, are therefore of great interest to patients. However, clinicians rarely advocate breathing retraining and access to this intervention is restricted for most patients due to the limited availability of suitable physiotherapists and poor integration of breathing retraining into standard care. We aimed to assess the effectiveness of a digital self-guided breathing retraining intervention.

Methods In this randomised controlled trial, we recruited patients from 34 general practices in the UK. Eligibility criteria for patients with asthma were broad, comprising a physician diagnosis of asthma, age of 16–70 years, receipt of at least one anti-asthma medication in the previous year, and impaired asthma-related quality of life (Asthma Quality of Life Questionnaire [AQLQ] score of <5·5). We developed a self-guided intervention, which was delivered as a DVD plus a printed booklet (DVDB). Participants were randomly assigned to receive either the DVDB intervention, three face-to-face breathing retraining sessions, or standard care, in a 2:1:2 ratio, for 12 months. Randomisation was achieved using the Southampton Clinical Trials Unit telephone randomisation service by use of random number generators. The primary outcome was the AQLQ score in the intention-to-treat population at 12 months. The trial was powered to show equivalence between the two active intervention groups, and superiority of both intervention groups over usual care. Secondary outcomes included patient-reported and physiological measures of asthma control, patient acceptability, and health-care costs. This trial was registered with International Standard Randomised Controlled Trial Number registry, number ISRCTN88318003.

Findings Between Nov 5, 2012 and Jan 28, 2014, invitations to participate in the study were sent to 15 203 patients with general practitioner-diagnosed asthma, of whom 655 were recruited into the study. AQLQ scores at 12 months were significantly higher in the DVDB group (mean 5·40, SD 1·14) than in the usual care group (5·12, SD 1·07; adjusted mean difference 0·28, 95% CI 0·11 to 0·44), and in the face-to-face group (5·33, SD 1·06) than in the usual care group (adjusted mean difference 0·24, 95% CI 0·04 to 0·44); AQLQ scores were similar between the DVDB group and the face-to-face group (0·04, 95% CI –0·16 to 0·24). There were no significant differences between the randomisation groups in FEV1 or fraction of exhaled nitric oxide. 744 adverse events occurred in 272 patients: 101 (39%) of 261 patients in the DVDB group, 55 (42%) of 132 patients in the face-to-face group, and 132 (50%) of 262 in the usual care group, with patients reporting one or more event. 11 (4%) patients in the DVDB group, four (3%) patients in the face-to-face group, and 20 (8%) patients in the usual care group had a serious adverse event.

Interpretation Breathing retraining programmes improve quality of life in patients with incompletely controlled asthma despite having little effect on lung function or airway inflammation. Such programmes can be delivered conveniently and cost-effectively as a self-guided digital audiovisual programme, so might also reduce health-care costs.

Funding UK National Institute of Health Research.

Copyright © The Author(s). Published by Elsevier Ltd. This is an open access article under the CC-BY NC-ND 4.0 license.
Research in context

Evidence before this study
Asthma is a complex, heterogeneous condition that affects patients in many ways; physically, psychologically, as well as affecting quality of life. Pharmacological treatments are effective, yet most patients continue to have ongoing symptoms and quality of life impairment despite the use of drug treatment. Many patients are interested in non-pharmacological treatment approaches, but the evidence base for most non-pharmacological interventions is inconclusive, with existing studies often underpowered or methodologically flawed. However, breathing retraining exercises have promising supportive evidence and are advocated as an add-on option in several evidence-based asthma guidelines. We identified two extensive recent systematic reviews of breathing retraining in asthma, which have differed in their conclusions; we therefore did not complete a systematic literature search ourselves. The 2012 US Agency for Healthcare Research and Quality analysis study concluded that non-pharmacological techniques can improve asthma symptoms and reduce the need for reliever medication, and the 2013 Cochrane review reported that trends for improvement were encouraging, and advocated further studies. Current National Health Service breathing retraining programmes involve face-to-face attendance with a suitably trained physiotherapist, but access is limited because of the scarcity of therapists and the logistical and financial challenges of making treatment available in routine care.

Methods

Study design and participants
This was a pragmatic 3-group, 12-month, observer-blinded, parallel-group randomised trial comparing the use of a DVD and booklet (DVDB) intervention with face-to-face physiotherapy or with a control group receiving usual care, in adults with asthma who were recruited from 34 UK general practices. Ethical approval for the study was provided by the NHS Health Research Authority South-Central—Hampshire B Research Ethics committee (12/SC/0353). A protocol has been published.¹

As a pragmatic, randomised trial,¹ participants had baseline characteristics measured, but broad entry criteria (with inclusion of smokers and no requirement for reversibility of airflow obstruction) and a minimally disruptive study procedure were used. To be included in the study, participants had to be aged 16–70 years, be registered at a medical practice for at least 12 months, have asthma diagnosed by a physician, have been prescribed at least 1 asthma medication in the previous year, achieve an asthma Quality of Life Questionnaire (AQLQ)¹² score of less than 5.5, and to provide written informed consent. Patients were excluded if they had concomitant chronic obstructive pulmonary disease (COPD) diagnosis with FEV₁ less than 60% predicted.

Randomisation and masking
Patients were randomly assigned (2:1:2) to receive the DVDB intervention, face-to-face physiotherapy, or usual care. This randomisation schedule was used because the face-to-face group was the most financially and logistically challenging to deliver to patients. Randomisation was done after eligibility assessment and informed consent; the research nurse telephoned the randomisation service provided by Southampton Clinical Trials Unit, where staff trained in registration and randomisation procedures

Added value of this study
We report the largest trial of breathing retraining in asthma to date, which used a pragmatic randomised controlled trial design. The main finding of this study is that asthma-related quality of life impairment is improved by a self-guided programme of physiotherapy-based breathing training delivered by a DVD and booklet, as an alternative model of delivery to the routine face-to-face method, with a magnitude of effect similar to that produced by increasing asthma medication. Patients perceived benefit from the self-guided programme despite little improvement in airway physiology or inflammation. We confirm reports from previous smaller studies that improvements in quality of life were seen with face-to-face physiotherapist-taught programmes compared with usual care. Additionally, we also showed that the DVD and booklet programme resulted in equivalent clinically relevant benefits more conveniently and inexpensively. In keeping with current evidence and meta-analysis, no adverse effects of either intervention were found.

Implications of all the available evidence
Our findings imply that the self-help intervention can be offered conveniently and cost-effectively as an adjuvant non-pharmacological treatment to many patients with asthma in routine care who have persisting impairment in quality of life despite standard pharmacological management.
accessed the web based Tenalea randomisation system. The research nurse then provided the participant with the appropriate materials and follow-up arrangements for the relevant study group. The research nurses who completed the exit assessments and medical record review were different from those completing the baseline assessment, and had no information about group allocations, with patients requested not to disclose their own treatment group. All analyses were completed by researchers masked to treatment allocation and without access to unmasked data.

Procedures
We developed an evidence-based, self-guided intervention delivered via a DVD plus a printed supporting booklet, which was based on an existing breathing retraining programme taught by physiotherapists and shown to be effective in poorly controlled asthma. The DVDB materials were developed by a multidisciplinary team including physicians, physiotherapists, health psychologists, communications technology specialists, and patient representatives, with extensive iterative qualitative patient input to optimise acceptability and effectiveness, and consisted of three elements. First, the DVDB intervention provided motivational components, explaining the rationale and addressing common concerns. Finally, supportive features (such as a daily planner and progress charts) were included for practicing and implementing the techniques in daily life.

The materials were piloted and finalised with 29 members of the target population, purposively sampled for diversity of age, gender, education, and symptom profile, by use of the person-based think aloud methods to elicit reactions and modify the materials based on the feedback received. The content of the DVD and the supporting booklet have been transferred to an internet-based version, and is freely available through the Breathe Study website.

Patient experiences and engagement were assessed by a study-specific questionnaire and by qualitative interviews with participants selected by purposive sampling until data saturation was achieved (appendix). Validated questionnaires used to assess secondary outcome measures were the Asthma Control Questionnaire (ACQ), which measured asthma symptoms; the Nijmegen Questionnaire (NQ), which measured symptoms related to hyperventilation and dysfunctional breathing; and the Hospital Anxiety and Depression Score (HADS), which had separate domains to measure anxiety and depression.

Potential patients, identified by computer searches of routine clinical records from general practices, received the study information and the AQLQ by mail. Questionnaires were then completed via post at 3 and 6 months, with a final assessment visit at 12 months done by a study nurse blinded to randomisation group, at which all baseline measures were repeated. If participants were unable to attend the final visit, questionnaire data were obtained by post or telephone.

Participants randomly assigned to the usual care group received usual medical care, with no additional attention to the baseline assessment. Participants randomly assigned to the DVDB intervention group were provided with the DVD and the booklet. Participants randomly assigned to the face-to-face group also received the booklet and worked to a standardised intervention schedule and were seen by a respiratory physiotherapist who was trained and skilled in providing breathing retraining for three one-to-one sessions, each of about 40 min duration, approximately once every 2 weeks after randomisation. The same physiotherapist, working to a structured protocol, delivered all the face-to-face sessions for all patients. Fidelity to treatment delivery was identified by use of a physiotherapist-completed checklist at every session, and a direct observation checklist completed by one author (AB) of a random sample of 5% of sessions. Protocol adherence was predefined as conforming to 90% of the checklist, and was 100% on both the physiotherapist and the observation checklists.

Outcomes
The primary outcome measure was the 12-month AQLQ score adjusted for the baseline values of prespecified covariates during statistical analysis. Secondary patient outcomes were questionnaire measures of asthma control, and measurements of airway physiology (FEV1, peak expiratory flow rate [PEFR], forced vital capacity [FVC]), airway inflammation (fraction of exhaled nitric oxide [FeNO]) measurements with Nioxx Min (Circassia, Oxford, UK), and asthma-related health resource use, in addition to a health-economic assessment (appendix). Validated questionnaires used to assess secondary outcome measures were the Asthma Control Questionnaire (ACQ), which measured asthma symptoms; the Nijmegen Questionnaire (NQ), which measured symptoms related to hyperventilation and dysfunctional breathing; and the Hospital Anxiety and Depression Score (HADS), which had separate domains to measure anxiety and depression.

Health resource use and prescriptions were obtained from the routine medical records on study exit, with asthma attacks, defined as the use of a course of oral corticosteroids for worsening respiratory symptoms or hospital admission. The economic evaluation report followed the CHEERS guideline. Adverse events in the full intention-to-treat population were reported by the local investigators and also gathered from the routine medical record at the end of the study by research nurses masked to the participants randomisation group. All significant (fatal or potentially life-threatening) events were collected, and all adverse events resulting in medical
attention that could plausibly be related to the study intervention were included, in the following categories: asthma-related; respiratory (including infections); ear, nose and throat; musculoskeletal; abdominal; neurological; and psychiatric events, detailed in the full study report.

**Statistical analysis**

On the basis of a previous breathing retraining trial, we assumed an SD of between-group AQLQ change between active treatment and control of 1.03, and a 25% smaller change between the two active intervention groups.
(SD 0.77). Treatments were deemed equivalent if the 95% CI for the mean difference was included between –0.3 and 0.3, with a two-tailed 5% significance level. Analysable sample sizes of 117 in the face-to-face group and 234 in the usual care and DVDB groups provided 90% power to detect a difference in mean AQLQ of 0.38 between active breathing retraining groups and the usual care group (as observed in the previous trials and of similar magnitude to pharmacological interventions in asthma), and more than 90% power to show equivalence between the two active intervention groups. Assuming a 10% dropout rate, we therefore aimed to recruit 650 patients.

The primary analysis was a repeated-measures mixed model using the 12-month AQLQ score across the three groups, with adjustments for prespecified covariates comprising baseline AQLQ score, general practitioner (GP) practice, age, gender, smoking status, British Thoracic Society (BTS) asthma treatment step (broadly equivalent to GINA step), and HADS and NQ scores. Pair-wise comparisons between DVDB and usual care groups, face-to-face physiotherapy and usual care groups (superiority studies), and DVDB and face-to-face physiotherapy groups (equivalence study) were made. Prespecified sensitivity analyses were analyses of the primary outcome in the per-protocol population (defined below) and used a range of recommended methods for missing data (appendix). Negative binomial regression models were constructed to estimate the incidence rate ratios of asthma attacks and rescue bronchodilator prescriptions in the intervention groups versus the usual care group. No adjustment was made for testing since all tests were prespecified with a priori effect sizes. Two statistical packages were used in the analysis, IBM SPSS statistics version 24 and STATA version 14. This trial was registered with International Standard Randomised Controlled Trial Number registry, number ISRCTN88318003.

Role of the funding source
Funding was provided by the UK National Institute of Health Research, Health Technology Assessment funding stream. The funder was not involved in the study design, data collection, data analysis, data interpretation, or in the writing of the report. The corresponding author had full access to all of the data and the final responsibility to submit for publication.

Results
Between Nov 5, 2012, and Jan 28, 2014, patients were recruited from 34 GP practices. Invitations were posted to 15203 patients and 1481 responses were received (10% response rate). Of those received, 801 (54%) of 1481 patients were eligible to participate in the study, with AQLQ score of more than 5·5 being the commonest ineligibility criterion—with 577 participants being excluded for this reason. 655 (82%) of 801 eligible patients were randomly assigned to treatment: 261 (40%) of 655 to the DVDB group, 262 (40%) to the usual care group, and 132 (20%) to the face-to-face group (figure 1). Baseline data (table 1) were similar between groups. The intention-to-treat population consisted of all participants randomly assigned to intervention, and all analyses were repeated in the per-protocol population, which included all participants with baseline and 12-month primary outcome data. There were few missing data for other questionnaires (<2%; appendix). Spirometry (FEV1, FVC, and FEV1/FVC ratio) was missing in 26 (4%) of 655 participants randomly assigned to treatment and FeNO in 49 (8%) of 655, with similar proportions between groups (appendix). 21 (3%) of 655 participants withdrew from the study (13 [5%] of 261 in the DVDB group, 3 [2%] of 132 in the face-to-face group, and 5 [2%] of 262 in the...
usual care group). The AQLQ was returned at 12 months by 556 (85%) of 655 participants, but all patients submitted a questionnaire at one or more of the follow-up points over the course of the study.

The mean AQLQ scores at 12 months were 5.40 (SD 1.14) in the DVDB group, 5.33 (1.06) in the face-to-face group, and 5.12 (1.17) in the usual care group. In the primary efficacy analysis (table 2, figure 2), the adjusted mean AQLQ score in the DVDB group compared with the usual care group was 0.24 (95% CI 0.04–0.44), and in face-to-face intervention compared with the usual care group was 0.24 (0.04–0.44). The adjusted mean difference between the DVDB and face-to-face interventions was 0.04 (0.01–0.16). In AQLQ subdomains (emotions, symptoms, activities, and environment), the largest improvements were in the emotion subdomain, with the DVDB group (0.38, 95% CI 0.16–0.60) and the face-to-face group (0.43, 0.16–0.71) both showing improvements compared with the usual care group. In the DVDB group, significant improvements over the usual care group were also seen in symptoms (0.24, 95% CI 0.05–0.42), activities (0.21, 0.02–0.39), and environment (0.32, 0.11–0.53) AQLQ subdomains; a similar improvement in the symptom subdomain was also seen in the face-to-face group compared with the usual care group (0.27, 0.04–0.49).

There were no significant differences in overall or individual domain scores between the DVDB and face-to-face groups. Significant differences were maintained in the pre-specified sensitivity analyses involving the results from the last observation carried forward, with similar outcomes shown by use of multiple imputation methods for missing data (appendix).

An analysis of individual patient responses was done that was recommended to quantify the proportion of patients in whom a minimum clinically important difference of 0.5 was met, because this analysis can provide additional information on the spectrum of the response and can be used to calculate numbers needed to treat (NNT). Clinically important improvements were seen in 161 (62%) of 261 patients in the DVDB group, 85 (64%) of 132 in the face-to-face group, and 146 (56%) of 262 in the usual care group, with corresponding percentages for deterioration of 14 (5%) in the DVDB group, 14 (5%) in the face-to-face group, and 14 (5%) in the usual care group. The adjusted mean difference was 0.04 (0.01–0.16). In AQLQ subdomains (emotions, symptoms, activities, and environment), the largest improvements were in the emotion subdomain, with the DVDB group (0.38, 95% CI 0.16–0.60) and the face-to-face group (0.43, 0.16–0.71) both showing improvements compared with the usual care group. In the DVDB group, significant improvements over the usual care group were also seen in symptoms (0.24, 95% CI 0.05–0.42), activities (0.21, 0.04–0.41), and environment (0.32, 0.11–0.53) AQLQ subdomains; a similar improvement in the symptom subdomain was also seen in the face-to-face group compared with the usual care group (0.27, 0.04–0.49).
group, 5 (4%) in the face-to-face group, and 24 (9%) in the usual care group, providing an NNT of eight for DVDB versus usual care, and seven for face-to-face versus usual care.

We observed no significant differences between groups in any secondary outcome measure, other than small magnitude but significant improvements in the depression component of the HADS in the DVDB group compared with the usual care group (mean adjusted difference –0·56, 95% CI –1·07 to –0·05). In particular, there were no significant within-group or between-group changes in airway obstruction (FEV₁, PEFR), inflammation (FeNO), ACQ or NQ scores, or in the anxiety component of the HADS (table 2).

Overall, 78 (12%) of 655 participants had one or more asthma attack during the 12 month study (table 3); 24 (9%) of 261 in the DVDB group, 15 (11%) of 132 in the face-to-face group, and 39 (15%) of 262 in the usual care group. The DVDB group showed a non-significant tendency to fewer asthma attacks compared with the usual care group (mean adjusted difference –0·56, 95% CI –1·07 to –0·05). In particular, there were no significant within-group or between-group changes in airway obstruction (FEV₁, PEFR), inflammation (FeNO), ACQ or NQ scores, or in the anxiety component of the HADS (table 2).

Table 3: Number of patients having asthma attacks over 12 months in the DVDB, face-to-face, and usual care treatment groups in the intention-to-treat and per-protocol populations, by number of corticosteroid courses used

<table>
<thead>
<tr>
<th></th>
<th>Intention-to-treat population</th>
<th>Per-protocol population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DVDB (n=261)</td>
<td>Face-to-face (n=132)</td>
</tr>
<tr>
<td></td>
<td>DVDB (n=215)</td>
<td>Face-to-face (n=110)</td>
</tr>
<tr>
<td>None</td>
<td>237 (91%)</td>
<td>117 (89%)</td>
</tr>
<tr>
<td>1</td>
<td>17 (7%)</td>
<td>10 (8%)</td>
</tr>
<tr>
<td>2</td>
<td>2 (1%)</td>
<td>4 (3%)</td>
</tr>
<tr>
<td>3</td>
<td>2 (1%)</td>
<td>0</td>
</tr>
<tr>
<td>4 or more</td>
<td>3 (1%)</td>
<td>0</td>
</tr>
</tbody>
</table>

DVDB=DVD and booklet.

744 adverse events occurred in 272 (42%) of 655 patients, with 101 (39%) of 261 patients in the DVDB group, 55 (42%) of 132 patients in the face-to-face group, and 132 (50%) of 262 in the usual care group, with patients reporting one or more event. 11 (4%) patients in theDVDB group, four (3%) patients in the face-to-face group, and 20 (8%) patients in the control group had a serious adverse event. Three deaths occurred that were considered not to be related to the study (one in the DVDB group and two in the usual care group).

Patient experiences of both interventions were favourable in those returning the 3-month questionnaires and in the qualitative interviews, with all of the 132 patients in the face-to-face group returning their questionnaire and 256 (98%) of 261 patients in the DVDB group reporting practising the techniques. Perceived benefits included increased control over breathing, reduced need for medication, feeling more relaxed, and improved quality of life (appendix).

Discussion

In our pragmatic randomised trial, we confirmed that three sessions of face-to-face physiotherapist-taught

www.thelancet.com/respiratory Vol 6 January 2018

25
breathing exercises improve disease-related quality of life for adults with asthma, and we have also shown that equivalent improvements can be achieved from a self-guided digital audiovisual programme. This programme was cost-effective and was considered to be an acceptable intervention method by patients.

Breathing retraining exercises are of considerable interest to people with asthma, and are recommended in evidence-based guidelines as possible adjuvant treatment for patients whose symptoms are not adequately controlled by pharmacological treatment. The current evidence base for breathing retraining in asthma has been assessed as convincing by some systematic reviews, and the most recent Cochrane review has reported encouraging trends, but called for further, adequately powered and methodically sound research. Current access to breathing retraining therapy within the NHS is limited by the availability of suitably trained physiotherapists and the logistical and economical challenges to providing face-to-face therapy to a wider population.

To our knowledge, we report the largest trial of breathing retraining in asthma to date. A pragmatic trial design was used, which aimed to recruit a representative patient population (with minimal exclusion criteria) and to minimally disrupt the process of normal care, to maximise generalisability of the results. The main finding of this study is that asthma-related quality-of-life impairment is equivalently improved by the routine face-to-face delivery method for breathing retraining and our alternative intervention of a digital self-guided programme of physiotherapy-based breathing retraining. We confirmed improvements in quality-of-life scores over usual care previously reported in smaller studies for face-to-face physiotherapist-taught programmes, and additionally showed that the DVDB programme results in equivalent clinically relevant benefits more conveniently and less expensively. To show that a new intervention is as effective as an established one, an equivalence margin must be specified for the primary outcome, and the 95% CI for the difference in effect between treatments contained within this margin. Our predefined equivalence margin was –0.3 to 0.3 AQLQ units, on the basis of a previously reported equivalence study. We actually observed a small numerical difference favouring the DVDB intervention over face-to-face treatment (0.04), with the 95% CIs being well within our predefined margin (–0.16 to 0.24), giving us confidence that the intervention itself would be widely acceptable.

The mean improvement from baseline AQLQ scores was 1.1 for both the DVDB and face-to-face groups, and 0.8 in the usual care group, with 0.5 equating to a clinically important improvement and 1.0 to a large improvement, suggesting that, on average, participants in all groups had clinically relevant improvements in quality of life over the study period. A previous pragmatic active comparator clinical trial in a population of adult patients with suboptimally controlled asthma, reported within-group improvements from baseline in AQLQ scores similar to those observed in our study by the addition of either a long-acting β agonist (mean difference from baseline 1.0) or of a leukotriene receptor antagonist (0.8). In our study, there was also a marked improvement from baseline in the usual care group, which is likely to relate to regression to the mean and trial involvement effects, but significant improvements remained in both intervention groups compared with the usual care group.

The qualitative and quantitative process assessments indicated that most participants engaged with breathing retraining, whether it was delivered face-to-face or via DVDB. In the 3-month postal questionnaires, there was an overall response rate of 388 (99%) of 393 patients in both intervention groups, with high proportions...
reporting positive engagement with the active interventions and at least some level of practice (256 [98%] of 261 in the DVDB group and 132 [100%] of 132 in the face-to-face group). The amount of practice reported by patients was variable, and higher in the face-to-face group than in the DVDB group, although this was not associated with improved outcomes and there was no apparent evidence of a dose-response association between the amount of practice in the techniques and clinical benefit. The aim of breathing retraining is to teach patients how to adjust their behaviour so that they can embed the techniques into their daily lives. Whether there is a minimum amount of practice required to learn and benefit from the breathing retraining techniques, and whether repeated training is needed at some future time, is not clear from this study and requires future investigation.

Although the significant group mean improvements that we report in both breathing retraining groups are below the minimum clinically important difference for an individual patient, the developers of the AQLQ instrument explicitly state that even if the mean difference between a treatment and a control is appreciably less than the smallest change, treatment might have an important effect on many patients.20 Similarly, one networked meta-analysis of pharmacological randomised trials assessing the magnitude of treatment effects on AQLQ,21 stated that the established within-patient minimum clinically important difference for ACQ and AQLQ is not achievable as a group-wise efficacy threshold between treatment groups in clinical studies. This meta-analysis reported that the mean improvements from the addition of a long-acting β agonist compared with control were 0·35 (95% CI 0·27 to 0·43), 0·20 (0·13 to 0·27) from the addition of leukotriene receptor antagonists, 0·01 (0·0 to 0·22) from the addition of theophylline, and 0·31 (0·20 to 0·41) from the addition of omalizumab.22 By comparison, improvements in our study from the DVDB intervention compared with usual care were 0·28 (95% CI 0·11 to 0·44), and 0·24 (0·04 to 0·44) for face-to-face physiotherapy compared with usual care. From a patient perspective, the quality of life improvements achieved from both physiotherapy-based programmes in this randomised trial were, therefore, of similar magnitude to those associated with commonly used pharmacological step-up strategies, and could be considered either in addition to, or instead of, increases in drug treatment. Whether improvements associated with pharmacological and non-pharmacological strategies are additive is not known. The heterogeneity of asthma is increasingly recognised, with evidence of identifiable clinical phenotypes.23,24 However, a weak association is consistently observed between patient-reported outcome measures and so-called objective parameters measuring airway physiology or inflammation,25,26 although a stronger association has been reported between outcomes and psychosocial factors.27,28 Personalised precision medicine aims to target treatments to individuals based on a multi-dimensional assessment incorporating biomarker, phenotypic, and psychosocial characterisation, and an individualised approach based on treatable traits has been advocated in airways disease.29 There is growing evidence that inflammatory biomarkers can identify individuals who will respond to targeted anti-inflammatory treatments in asthma.30-32 It has been less clear how to meet the needs of symptomatic individuals without objective evidence of an abnormal and pharmacologically modifiable pathway. We believe that it is now possible to offer this simple non-pharmacological intervention as a part of a rational overall asthma treatment strategy.

The use of DVDs has declined since the inception of the study, with a corresponding growth in online and streamed sources for provision of digital information and entertainment. Accordingly, to make this intervention accessible to clinicians, researchers, and people with asthma, we have made the content of the DVD and the supporting booklet freely available online through the Breathe study website. Additionally, we are in the process of producing a web-optimised version of the intervention for online use, in collaboration with our partner patient charity, Asthma UK, and we anticipate that this material will be freely available to patients and professionals in 2018. The low cost of providing an internet-based intervention, the ease of access of content and the absence of adverse outcomes using such approaches indicate that this evidence-based non-pharmacological intervention can now be offered to people with asthma with persisting quality-of-life impairment despite current asthma medication. There is a need to stress to patients that this intervention is in addition to, not instead of, current medication, and that it does not cure asthma, but rather is a means to improve quality of life.

Contributors
The original study conception and overall leadership came from MT and AB. The senior statistician was AL, who supervised the trial statistician MT, who did the statistical analyses. Study raw data was also available to the health economic team (JR, SZ, GY) and the chief investigator (MT). LF provided leadership for the development of the digital behavioural intervention and the process assessments. SG, MM, PL, RD, DP, IDP, and STH provided input into the original trial design, supported the trial management and advised on interpretation and presentation of results. JR designed the health economic component and was a member of the trial management group, with the health economic analyses done by SZ and GY. EA-C and SK were involved in the digital intervention development process and in the qualitative and quantitative process assessments. JV was involved in the original study conception (at the time being the research lead for Asthma UK) and provided public and patient involvement input, along with MS-W (both of whom attended trial management meetings as PPI representatives). DG was involved in the intervention development. FW and LT were involved in the organisation and delivery of the study. All authors were involved in commenting on the manuscript and have approved the submitted version.

Declaration of interests
AB reports a National Institute for Health Research Senior Research Fellowship. LF reports grants from the National Institute of Health Research during the conduct of the study. JR is a member of the National Institute for the Breathe study see https://www.breathestudy.co.uk
Institute of Health Research Health Technology Assessment (HTA) programme Editorial Board, outside the submitted work. EA-C reports grants from the National Institute of Health Research HTA outside the conduct of the study. MM reports grants from the National Institute of Health Research HTA outside the conduct of the study. RD reports personal fees from Teva Pharmaceuticals; grants and personal fees from Novartis; and personal fees and other support from Synephagen outside the submitted work; he is also Chairman of the European Respiratory Society Clinical Research Collaboration and SHARP. DP reports board membership at Aerocine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; consultancy for Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, and Theravance; grants from Aerocine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Respiratory Effectiveness Group, Teva Pharmaceuticals, Theravance, UK National Health Service, and Zentiva; speaking fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Skypharma, and Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma and Teva Pharmaceuticals; travel grants from Aerocine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; funding for patient enrolment from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva; payment for publication of educational materials from Mundipharma and Novartis; and non-financial support from the Efficacy and Mechanism Evaluation programme and Health Technology Assessment outside the submitted work; DP also has stock or stock options from AKL Research and Development Ltd, which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum options from AKL Research and Development Ltd, which produces and manufactures; and non-financial support from the Efficacy and Mechanism Evaluation programme and Health Technology Assessment from the Efficacy and Mechanism Evaluation programme and Health Technology Assessment, Mundipharma, Napp, Novartis, and Teva Pharmaceuticals; funding for patient enrolment from Chiesi, Novartis, Teva Pharmaceuticals, and Zentiva; payment for publication of educational materials from Mundipharma and Novartis; and non-financial support from the Efficacy and Mechanism Evaluation programme and Health Technology Assessment from the Efficacy and Mechanism Evaluation programme and Health Technology Assessment.

Acknowledgments
This article presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Reference